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Abstract
Background: Although oral replacement with high doses of vitamin B12 is both effective and safe for the
treatment of B12 deficiency, little is known about patients' views concerning the acceptability and
effectiveness of oral B12. We investigated patient perspectives on switching from injection to oral B12
therapy.
Methods: This study involved a quantitative arm using questionnaires and a qualitative arm using semi-
structured interviews, both to assess patient views on injection and oral therapy. Patients were also
offered a six-month trial of oral B12 therapy. One hundred and thirty-three patients who receive regular
B12 injections were included from three family practice units (two hospital-based academic clinics and one
community health centre clinic) in Toronto.
Results: Seventy-three percent (63/86) of respondents were willing to try oral B12. In a multivariate
analysis, patient factors associated with a "willingness to switch" to oral B12 included being able to get to
the clinic in less than 30 minutes (OR 9.3, 95% CI 2.2–40.0), and believing that frequent visits to the health
care provider (OR 5.4, 95% CI 1.1–26.6) or the increased costs to the health care system (OR 16.7, 95%
CI 1.5–184.2) were disadvantages of injection B12. Fifty-five patients attempted oral therapy and 52 patients
returned the final questionnaire. Of those who tried oral therapy, 76% (39/51) were satisfied and 71% (39/
55) wished to permanently switch. Factors associated with permanently switching to oral therapy included
believing that the frequent visits to the health care provider (OR 35.4, 95% CI 2.9–432.7) and travel/
parking costs (OR 8.7, 95% CI 1.2–65.3) were disadvantages of injection B12. Interview participants
consistently cited convenience as an advantage of oral therapy.
Conclusion: Switching patients from injection to oral B12 is both feasible and acceptable to patients. Oral
B12 supplementation is well received largely due to increased convenience. Clinicians should offer oral B12
therapy to their patients who are currently receiving injections, and newly diagnosed B12-deficient patients
who can tolerate and are compliant with oral medications should be offered oral supplementation.
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Background
Intramuscular injections of vitamin B12 (cobalamin) have
been the mainstay of B12 deficiency treatment for decades.
However, because approximately 1% of orally ingested
B12 is absorbed via simple diffusion throughout the gas-
trointestinal tract (i.e., independently of intrinsic fac-
tor)[1,2], oral replacement with high doses of cobalamin
is both effective and safe, regardless of the etiology of B12
deficiency [1,3-12].
Oral B12  therapy would decrease physician burden,
increase patient control over therapy, and avoid patient
discomfort and inconvenience. Switching patients from
B12 injections to oral therapy would also result in savings
to the health care system [13]. While some commentators
have argued that clinicians should switch to oral B12 ther-
apy [13-15], little is known about patients' views concern-
ing the acceptability and effectiveness of oral B12.
Efforts to switch patients who are well established on
parenteral therapy (and who have previously been told
they require lifelong injections) may fail without an
understanding of what factors influence patient accepta-
bility of oral therapy. Therefore, we combined qualitative
and quantitative methods to test the hypothesis that
patients offered oral B12 are willing to switch to oral ther-
apy and to explore the reasons for their choice.
Methods
We administered a questionnaire to patients with B12 defi-
ciency, offered the option of a six-month trial of oral
replacement, and administered a follow-up question-
naire. Throughout the study, semi-structured interviews
were conducted for the qualitative arm. We received ethics
approval from the Sunnybrook and Women's College
Health Sciences Centre Research Ethics Board. All patients
provided informed consent.
Quantitative arm
Data collection
The study took place at two academic family practice units
and a community health centre with diverse practice pro-
files in Toronto. We included all patients who received
regular injections (i.e., every 1 to 3 months), regardless of
age and etiology of B12 deficiency. We excluded patients if
their last injection occurred more than three months
before the start of patient recruitment, if they had left the
practice, if their B12 therapy had been discontinued or if
they had already switched to oral therapy, if they did not
speak English and did not have access to a translator, or if
they had been recently diagnosed with a serious illness.
After applying these criteria, 133 patients were included in
the study (Figure 1).
The recruitment cover letter included one sentence
describing the equivalency of oral B12 therapy to injec-
tions: "Studies have shown that vitamin B12 pills are just
as effective and safe as B12 injections." Educational ses-
sions on the effectiveness of oral therapy were held with
the nursing staff (since they administer the injections) at
all sites, and they were encouraged to pass this informa-
tion on to their patients. As well, contact information for
the study investigators was provided to the patients in case
they had any questions.
We placed the initial questionnaire [see Additional file 1 ]
in patients' charts to be completed at their next visit for a
B12  injection. The initial questionnaire elicited demo-
graphic data, medication history, logistical aspects of B12
related visits, history of past B12 therapy, and attitudes
about injection and oral therapy. Non-responders
received up to two telephone reminders.
Patients willing to try oral therapy were given a six-month
supply of B12 tablets (one 1000 µg tablet daily), and were
offered testing of serum B12 levels at baseline (one month
after their last injection) and after the six-month trial.
Patients had the option to withdraw from the trial and
return to injections at any time for any reason. A follow-
up questionnaire was placed in the charts of patients who
tried the pills. This questionnaire re-assessed patients' atti-
tudes about the different forms of B12 therapy and asked
whether they would continue on oral supplementation or
return to injection therapy (see Additional file 2).
Statistical analyses
Where variables were not already dichotomous (e.g., for
satisfaction with injections, the questionnaire listed "very
satisfied," "satisfied," "neutral," "unsatisfied," and "very
unsatisfied" as choices), we dichotomized the variable of
interest (e.g., "satisfied" vs. "neutral/unsatisfied"). To
ascertain the relationship between questionnaire
responses and preference for oral therapy (as "willingness
to switch" and "permanently switching") we performed
bivariate and multivariate analyses. We used a p-value of
0.20 (for the continuity-adjusted χ2 and Fisher's exact
tests) as the cut-off for inclusion of individual patient fac-
tors into multivariate logistic regression models. We then
performed backwards stepwise regression to determine
statistically significant relationships after adjustment. We
generated both crude and adjusted odds ratios with 95%
confidence intervals.
Qualitative arm
Participants and setting
One investigator (D.C.) conducted 17 semi-structured
interviews in a private meeting room at the family practice
unit. A purposive sample was selected amongst those will-
ing to be interviewed to reflect diversity in terms of sex,BMC Family Practice 2005, 6:8 http://www.biomedcentral.com/1471-2296/6/8
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age, willingness to switch, and final choice of therapy after
the trial of B12 pills. These interviews were performed at
various stages of the study (before, during, and after the
trial of oral therapy). Amongst the 17 participants, four
were selected from those not willing to switch, while of
the 13 who were willing to try oral therapy, six were inter-
viewed prior to, two during, and five after the trial of oral
therapy.
Data collection and analysis
The interviews were audiotaped and transcribed. They
lasted 20–30 minutes, with questions about the patient's
knowledge and history of their B12 therapy, his or her rela-
tionship with health care providers, perceived advantages
and disadvantages of both pills and injections, and atti-
tudes about past and current B12 therapy. Analyses of the
transcripts were performed independently by two investi-
gators (J.K. and D.T-K.), using a three-step content analy-
sis approach to identify and collate relevant themes [16].
Through a process of clarification, confrontation, and
consensus, we reached agreement regarding the themes
and sub-themes.
Results
Quantitative arm
For our initial questionnaire, we received responses from
86 out of the sample of 133 patients, for a response rate of
64.7%. Selected characteristics of the study population are
presented in Table 1. Non-responders were younger and
more likely to be female.
Willingness to switch to oral B12
Sixty-three of our 86 respondents reported a willingness
to switch to oral therapy. A large number of patient factors
had no clear statistical relationship to a "willingness to
switch" to oral therapy (i.e., p > 0.20) and were excluded
from the multivariate model: age, education, income,
drug insurance coverage, study site, number of prescrip-
tion medications, mode of travel to the clinic, years of past
B12 therapy, number of non-B12 related visits per month,
Flow diagram of patients in study Figure 1
Flow diagram of patients in study.
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Table 1: Selected characteristics of study population and a comparison of responders vs. non-responders
Responders n = 86 Non-responders n = 47 p-value
Mean age – Yr ± SD 72 ± 15 65 ± 20 0.03
Female sex – No. (%) 48 (56) 37 (79) 0.009
Level of education completed
High school or less 28 (33)
Some post-secondary education 21 (25)
Bachelors degree or more 35 (42)
Annual household income
Less than $40K 40 (53)
$40–79K 20 (26)
$80K or greater 16 (21)
Self-reported perception of health
Above average 25 (29)
Average 40 (47)
Below average 20 (24)
Prescription medications taken
0 8 (10)
1 to 3 46 (55)
4 to 6 16 (19)
7 + 14 (17)
Monthly episodes of forgetting medications
0 45 (54)
1–2 26 (31)
3+ 12 (14)
Years on B12 therapy
0 to 2 19 (24)
3 to 5 25 (31)
6 to 10 17 (21)
11 to 19 13 (16)
20+ 6 (8)
Frequency of B12 injections
Less than once monthly 9 (10)
Once monthly 74 (86)
More than once monthly 3 (3)
Satisfaction with B12 injections
Satisfied 22 (26)
Neutral 59 (69)
Unsatisfied 5 (6)
Monthly visits to doctor for other reasons
0 49 (60)
1 23 (28)
2 + 10 (12)
Mode of travel to visit doctor
Personal vehicle 49 (58)
Public transit 23 (27)
Walk 9 (11)
Taxi 4 (5)
Travel time to visit doctor
< 15 min 27 (32)
15–29 min 29 (35)
30–44 min 20 (24)
45–59 min 5 (6)
60+ min 3 (3)
Patients at each study site
Sunnybrook Campus, SWCHSC* 51 (59)
Flemingdon Health Centre 19 (22)
Women's College Campus, SWCHSC* 16 (19)
* Sunnybrook and Women's College Health Sciences CentreBMC Family Practice 2005, 6:8 http://www.biomedcentral.com/1471-2296/6/8
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improvement in perceived well-being since initiating B12
injections, several perceived disadvantages of injections
(risk of complications, travel/parking costs), and several
perceived disadvantages of pills (take too many pills
already, would have to pay for them, won't work as well
as injections).
The following factors were included in the multivariate
model: gender, time to clinic, satisfaction with past B12
injections, several perceived disadvantages of injections
(shots are painful, frequent visits to see MD/nurse, cost to
health care system), and one perceived disadvantage of
pills (won't see MD/nurse as often). Factors associated
with willingness to switch after multivariate adjustment
were: being able to get to the clinic more quickly (i.e., in
less than 30 minutes) (OR 9.29, 95% CI 2.16–39.97), and
believing that injection therapy is disadvantageous due to
the need for frequent visits to health care provider (OR
5.41, 95% CI 1.10–26.56) and the increased costs to the
health care system (OR 16.68, 95% CI 1.51–184.22)
(Table 2).
Trial of oral therapy
Of the 63 patients who were willing to switch to oral B12
therapy, eight changed their minds before the trial started.
Therefore, 55 patients were started on oral B12. Five
dropped out and three were lost to follow-up, leaving 47
patients who completed the six-month trial. Reasons cited
for discontinuing oral therapy included fatigue, neurolog-
ical symptoms, and gastrointestinal intolerance.
Fifty-two patients returned the follow-up questionnaire.
Over three-quarters (39 of 51 respondents) reported
being satisfied or very satisfied with oral therapy. Only 8%
of patients (4/51) perceived that they felt worse with pills,
while 23.5% (12/51) felt better and the rest felt the same.
Self-reported compliance was good; 48 patients or 92%
reported forgetting to take the pills two times or less per
month. Thirty-nine patients (71% of the 55 who actually
switched) stated that they wished to permanently switch
to B12 pills. Of the 35 patients who reported feeling the
same with the pills as with injections, 28 (80%) chose
pills.
Again, many patient factors had no association with a
desire to permanently switch to oral B12. Patient factors
that on bivariate analyses had a p-value of less than 0.20
and were consequently included in the multivariate
model were: patient beliefs that frequent visits to see the
doctor or nurse and the associated travel/parking costs are
disadvantages of injections, and the belief oral B12 would
add unnecessarily to an already large number of pre-
scribed oral medications. Table 3 presents the factors sig-
nificantly associated, after multivariate adjustment, with
permanently switching to oral therapy: agreeing that dis-
advantages of injections included frequent visits to see the
doctor/nurse (OR 35.41, 95% CI 2.90–432.70) and
travel/parking costs (OR 8.66, 95% CI 1.15–65.30).
Serum B12 levels
Baseline and post-intervention serum B12  levels were
obtained for 39 of the 55 patients who switched to pills
(Figure 2). The mean serum level increased from 387 to
698 pmol/L (p < 0.0001) (reference range: ≥ 180 pmol/L,
unlikely to have B12 deficiency). Only one patient's serum
level decreased but even she remained within the normal
range.
Table 2: Patient factors associated with willingness to switch to oral therapy on initial questionnaire.
No. (%) of subjects Unadjusted Adjusted*
Patient factor Willing to switch n = 63 Not willing to switch n = 23 OR (95% CI) p-value OR (95% CI) p-value
Time to clinic
0–29 minutes 49 (87) 7 (13) 9.34 <0.001 9.29 0.003
30+ minutes 12 (43) 16 (57) (3.14–27.78) (2.16–39.97)
Perceived disadvantages of injections
Frequent visits to see MD/nurse
Agree 38 (86) 6 (14) 4.31 0.010 5.41 0.038
Disagree 25 (60) 17 (40) (1.49–12.42) (1.10–26.56)
Cost to health care system
Agree 26 (93) 2 (7) 7.38 0.010 16.68 0.023
Disagree 37 (64) 21 (36) (1.59–34.23) (1.51–184.22)
* Adjusted for patient factors at least weakly associated (i.e., p < 0.20) with a willingness to switch to oral B12 therapy in bivariate analyses: gender, 
time to clinic, satisfaction with past B12 injections, perceived disadvantages of injections (shots are painful, frequent visits to see MD/nurse, cost to 
health care system), perceived disadvantage of pills (won't see MD/nurse as often)BMC Family Practice 2005, 6:8 http://www.biomedcentral.com/1471-2296/6/8
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Table 3: Patient factors associated with permanently switching to oral therapy on follow-up questionnaire
No. (%) of subjects Unadjusted Adjusted*
Patient factor Choosing oral 
therapy n = 39
Choosing injection 
therapy n = 13
OR (95% CI) p-value OR (95% CI) p-value
Perceived disadvantages of 
injections
Frequent visits to see MD/nurse
Agree 27 (96) 1 (4) 27.00 <0.001 35.41 0.005
Disagree 12 (50) 12 (50) (3.14–231.87) (2.90–432.70)
Travel/parking costs
Agree 23 (92) 2 (8) 7.91 0.016 8.66 0.036
Disagree 16 (59) 11 (41) (1.54–40.60) (1.15–65.30)
* Adjusted for patient factors at least weakly associated (i.e., p < 0.20) with permanently switching to oral B12 therapy in bivariate analyses: perceived 
disadvantages of injections (frequent visits to see MD/nurse, travel/parking costs), perceived disadvantage of pills (take too many pills already)
Serum B12 concentrations before and after six months of oral B12 therapy for forty patients Figure 2
Serum B12 concentrations before and after six months of oral B12 therapy for forty patients.
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Qualitative arm
The mean age of interview participants was 71 (range 54–
92) years, with 7 men and 10 women.
Perceived efficacy of B12 therapy
Some patients felt that the B12 injections they had been
receiving in the past were effective: "I find it gives me more
energy." Patients who expressed this view were often not
willing to switch to oral therapy, or if they did try the pills,
they eventually went back to injections. Others felt that
the injections hadn't helped much: "There is a little feeling
that, 'Oh, I'm taking this. I should feel better,' but I'm not
sure if I do." These patients tended to switch permanently
to oral therapy.
When asked about the anticipated efficacy of oral therapy,
some patients, particularly those who were not willing to
switch, were sceptical: "Well, I don't think it will work. If
the doctors suggested that I needed to go on the injec-
tions, I'm certainly pretty sure that the pills are not going
to work. Otherwise he'd have put me on pills, would he
not?" Many others were unsure about the efficacy of oral
therapy.
Reasons for switching to oral therapy
Nearly every patient cited convenience as an advantage of
switching to B12 pill. Other advantages of oral therapy
included savings to the health care system and ease of
travel. Cited disadvantages of injections included
decreased compliance due to the need for frequent visits
and potential complications associated with injections. A
number of patients decided to switch because they were
interested in participating in a research study. Some
patients acknowledged that oral therapy would benefit
those who are averse to needles, however, needles did not
bother most of the patients interviewed: "...needles don't
bother me, because – well, I don't know. They just don't
seem to bother me. I know some people are very con-
cerned about it."
Satisfaction with oral therapy
For both patients interviewed during their trial of oral B12
and for three of the five patients interviewed afterward, all
of whom permanently switched to oral therapy, there was
a high level of satisfaction with oral B12. One patient even
reported feeling better on oral B12: "Well, I'm more level.
I don't feel at the end of the month that I'm running out
of energy. I'm quite well aware of that." (see Additional
file 3).
Reasons for staying with/switching back to injection therapy
Disadvantages of switching to oral therapy included hav-
ing to take an additional oral medication, fear of side
effects, concern about swallowing difficulties, the incon-
venience of taking a medication daily, and the potential
for losing contact with health care providers and the
opportunity for minor drop-in consultations. Some
patients were under the impression that injections would
work more quickly and directly.
Two patients who switched back to injections after trying
the pills were interviewed. These patients switched back
due to side effects – one cited neurological and gastroin-
testinal symptoms (her post-trial serum B12 level was sig-
nificantly increased from baseline) and the other cited
decreased energy (his post-trial serum B12 level was not
available). (see Additional file 4).
Discussion
We found that switching patients from injection to oral
B12 is both feasible and acceptable to patients. Of those
who responded to our initial questionnaire, nearly three-
quarters were willing to try oral B12, and of those who did
switch, most were satisfied and the majority wished to
remain permanently on oral therapy. These patients
believed that injections are disadvantageous because they
are associated with too many visits to their health care
provider and with higher patient costs (in terms of travel
and parking expenses). In the qualitative arm of our study,
most patients cited convenience as the reason for wanting
to switch from injections to pills. We were also able to
confirm findings from other studies indicating that oral
B12 is biochemically equivalent to, if not better than,
parenteral therapy.
One non-intuitive finding from the initial questionnaire
assessing the factors associated with trying oral therapy
(Table 2) was that those who were able to get to the clinic
more quickly (i.e., in fewer than 30 minutes) were more
likely to try switching. While one might expect that those
who live closer to their clinic would benefit less from the
convenience of not having to visit their health care
provider as frequently, we speculate that perhaps these
patients are more comfortable with trying oral therapy
because they know that it is easy for them to access care if
they need it, rather than having to rely on regular visits for
their injections to see their primary care provider. Another
interesting finding – that the perception of travel expenses
being a disadvantage of the injections was not associated
with being willing to try injections but was associated
with permanently switching after the trial – suggests that
perhaps patients did not realize the benefit of the saved
travel costs until several visits had been averted.
By monitoring trough serum B12 levels (i.e., 1 month after
their last injection) and again 6 months after oral therapy,
we observed that one patient was a non-responder (i.e.,
serum level decreased), and 4 patients had serum levels
that increased but remained below 295 pmol/L (a level
considered by some to be borderline B12 deficient)[17].BMC Family Practice 2005, 6:8 http://www.biomedcentral.com/1471-2296/6/8
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This represents 13% out of the 39 patients who under-
went testing, suggesting that follow-up testing may be
warranted with serum B12 levels and, if available, func-
tional tests such as serum homocysteine and methly-
malonic acid. The sub-optimal response in these patients
may be due to patient non-compliance or sub-optimal
dosing (we used a 1-mg daily dose, rather than the 2-mg
daily dose used by Kuzminski et al.) [8]. Further studies
may be required to clarify the optimal dosing regimen for
oral therapy.
The primary strength of our study was that we achieved
triangulation through the use of both quantitative and
qualitative methods. By using questionnaires, we were
able to provide estimates such as switch rates and levels of
patient satisfaction; with the qualitative arm, we were able
to more thoroughly explore patient perspectives.
The main limitation of our study was the relatively small
sample size for the quantitative arm, which led to large
confidence intervals for the estimates of the relationship
between patient factors and switching to oral B12. How-
ever, the sample was large enough to identify a number of
patient factors associated with switching from injection to
oral therapy and to determine that patient attitudes
toward oral B12 therapy are greatly influenced by its con-
venience. A second limitation was that we did not assess
the knowledge and attitudes of our patients' physicians
and nurses, as they may have influenced patient's expecta-
tions and perceptions regarding the effective of oral B12
therapy. Finally, another limitation was the potential par-
ticipant bias, evidenced by the differences between
responders and non-responders in terms of age and sex.
However, among the responders, neither age nor sex was
significantly associated with switching to oral therapy,
suggesting that any differences between participants and
non-participants were likely irrelevant.
While there have been several studies examining physi-
cians' perspectives on switching from intramuscular to
oral therapy [18-21], we know of few studies that have
examined patients' views. In a recent study that involved
switching forty patients to oral therapy, the authors
reported that 83% preferred the oral form [15]. However,
no further details on patient perspectives were reported.
Another study found that patients become very attached
to receiving their injections; after identifying 48 patients
who did not meet diagnostic criteria for B12 deficiency and
providing educational sessions to encourage discontinu-
ing injections, 38% stated they would leave the practice if
denied their injections [22]. Explanations suggested by
the authors include the reluctance to discontinue a ther-
apy initiated by a trusted and respected physician, and the
belief that intramuscular injections are more potent and
more effective than medications taken orally. While the
perception of increased potency of injections was reported
by some patients in the qualitative arm of our study, this
belief was supported by only 20% of respondents in the
initial questionnaire (data not shown).
While oral B12  therapy may be acceptable for most
patients, it may not be appropriate for those who will not
be compliant with oral medications, such as patients with
significant memory impairment or cognitive dysfunction,
unless they have caregivers who could ensure compliance.
Oral therapy also may not be appropriate for those with
swallowing difficulties; for such patients, sublingual B12
therapy, which has been shown to be equally effective,
may more appropriate [23].
Conclusion
In summary, the results of our study suggest that clinicians
should offer oral B12 therapy to their patients who are cur-
rently receiving injections if they can tolerate and are com-
pliant with oral medications. Most patients who switch
from parenteral to oral therapy are satisfied and wish to
stay permanently on oral therapy. They often cite the
inconvenience and the travel-related expenses associated
with frequent visits to the doctor as disadvantages of
parenteral therapy. Therefore, oral B12 therapy is generally
well-received by patients, and should be considered by cli-
nicians as a superior alternative to the traditional injec-
tions for most patients.
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